A GMP cell therapy facility to test cell based therapies

用于测试细胞疗法的 GMP 细胞治疗设施

• 批准号: MR/M009149/1
• 负责人: Danny McAuley
• 金额: $ 3.19万
• 依托单位: Queen's University Belfast
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2015
• 资助国家: 英国
• 起止时间: 2015 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=MR%2FM009149%2F1
• 关键词: GMP; cell; therapy; facility; test

Cell-based therapies represent the cutting edge of research for new treatments for a variety of conditions. The global commercial cell therapy industry was estimated to have an annual turnover of £600M in 2011, and is estimated to grow to £120BN by 2025. Currently there is a significant gap in the UK's clinical research capabilities and infrastructure to deliver trials involving cell-based therapy largely because cell therapies require specialised facilities to safely manage the cells for human administration.The specific aim of this proposal is to develop a cell therapy facility to enable the testing of cell therapies in clinical trials. This project will facilitate the delivery of clinical trials to investigate cell-based therapies (currently under development by researchers at QUB) for both respiratory failure in the critically ill and vision loss.This state of the art facility will provide capacity for management from the storage and subsequent preparation of cell therapies for patient administration, through to the manufacturing of cell based therapies. This will strategically enhance the capabilities of the UK in cell-based therapies and provide a foundation for future significant health and socio-economic benefits to the UK.It will be established as a recognised UK centre for translational research in respiratory medicine.The facility will be available for use by external universities, hospitals and companies.

基于细胞的疗法代表了各种疾病新疗法研究的前沿。据估计，全球商业细胞治疗行业在2011年的年营业额为6亿英镑，预计到2025年将增长到1.2亿英镑。目前，英国的临床研究能力和基础设施在提供涉及细胞疗法的试验方面存在很大差距，这主要是因为细胞疗法需要专门的设施来安全地管理用于人类管理的细胞。该提案的具体目标是开发一种细胞疗法设施，以便在临床试验中进行细胞疗法的测试。该项目将促进临床试验的交付，以研究基于细胞的疗法（目前正在由QUB的研究人员开发），用于重症患者的呼吸衰竭和视力丧失。这一最先进的设施将提供从储存和随后制备用于患者给药的细胞疗法到基于细胞的疗法制造的管理能力。这将战略性地增强英国在细胞疗法方面的能力，并为英国未来的重大健康和社会经济效益奠定基础。该中心将被建立为英国公认的呼吸医学转化研究中心，该设施将可供外部大学、医院和公司使用。

项目成果

Repair of acute respiratory distress syndrome by stromal cell administration (REALIST) trial: A phase 1 trial.

• DOI: 10.1016/j.eclinm.2021.101167
• 发表时间: 2021-11
• 期刊: EClinicalMedicine
• 影响因子: 15.1
• 作者: Gorman E;Shankar-Hari M;Hopkins P;Tunnicliffe WS;Perkins GD;Silversides J;McGuigan P;Krasnodembskaya A;Jackson C;Boyle R;McFerran J;McDowell C;Campbell C;McFarland M;Smythe J;Thompson J;Williams B;Curley G;Laffey JG;Clarke M;McAuley DF;O'Kane CM
• 通讯作者: O'Kane CM

Mitochondrial Transfer via Tunneling Nanotubes is an Important Mechanism by Which Mesenchymal Stem Cells Enhance Macrophage Phagocytosis in the In Vitro and In Vivo Models of ARDS.

• DOI: 10.1002/stem.2372
• 发表时间: 2016-08
• 期刊: Stem cells (Dayton, Ohio)
• 作者: Jackson MV;Morrison TJ;Doherty DF;McAuley DF;Matthay MA;Kissenpfennig A;O'Kane CM;Krasnodembskaya AD
• 通讯作者: Krasnodembskaya AD